Drug Profile


Alternative Names: SAR-245409; XL-765

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Exelixis
  • Developer EMD Serono; Exelixis; Sanofi
  • Class Antineoplastics; Pyrazoles; Pyridones; Pyrimidines; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • No development reported Chronic lymphocytic leukaemia; Glioblastoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Discontinued Breast cancer; Ovarian cancer

Most Recent Events

  • 18 Jul 2016 Biomarkers information updated
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Monotherapy) in USA (PO, Tablet)
  • 27 Aug 2015 Sanofi completes enrolment in its phase I/II trial for Solid tumours (Monotherapy, Combination therapy) in USA, Belgium, France and Spain (NCT01587040)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top